https://microrna-receptor.com/....index.php/effect-of-
While change rates into aggressive lymphoma were similar between both groups, there were more extra malignancies after R-B weighed against R-CHOP (6 versus 2 instances). In FL1-2, R-B reached a greater 3-year PFS (79% versus 47%, P less then 0.01), while there was no considerable distinction regarding OS or transformation. Aided by the restrictions of a retrospective evaluation, these outcomes recommend an advantage for R-CHOP over R-B in FL3A or FL1-2-3A. Confirmator
إعجاب
علق
شارك
